Every day, the sun rises on Wall Street, and a plethora of professional analysts wake to issue new opinions on stocks. Here at the Fool, we use our "This Just In" column to examine some of these picks -- and the track records of the companies behind them -- so individuals can make better investing decisions.
In addition to following professional banks, anyone can use Motley Fool CAPS to monitor the collective opinions of more than 140,000 members, many of whom demonstrate better investing insight than published analysts do.
More and more top-performing CAPS members have been turning to the bullish side of Allos Therapeutics
The biopharmaceutical company recently received FDA approval for its relapsed or refractory peripheral T-cell lymphoma (PTCL) treatment, Folotyn, and many CAPS members are bullish on its future revenue potential. Relapsed or refractory PTCL is an aggressive type of non-Hodgkin's lymphoma, similar to diffuse large B-cell lymphoma, which Microsoft
Companies like Spectrum Pharmaceutical
Allos Therapeutics is moving to make Folotyn available for sale in the U.S. and is boosting its sales staff with plans for a full-scale launch early next year. It raised $93 million in an equity offering to help fund its marketing efforts, and it is also looking at possible expanded indications for the drug, which investors see as a big positive. Many CAPS members agree with Jim Cramer on the bullish outlook for Allos.
Do you think Allos Therapeutics deserves its five-star status? Add your thoughts in the comments box below, or head over to CAPS to rate the company and check out all the information the community offers, absolutely free.